Mineralys Therapeutics, Inc. — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Form 8-K filed 2026-10-19 reports Item 5.02 events: departure of directors or officers, and/or election/appointment of officers with compensatory arrangements. No specific names, dollar amounts, dates, or transaction details are provided in the available filing metadata. Full details require access to the complete exhibit documents.
Why this rating
Routine officer/director transition disclosure. No material financial amounts, strategic shifts, or business impact specified in summary data.
Extracted items
- 5.02 exec change
- 9.01 exhibits
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.